No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19

Nanomedicine (Lond). 2020 Oct;15(24):2411-2427. doi: 10.2217/nnm-2020-0286. Epub 2020 Sep 2.

Abstract

There is an urgent need for safe and effective approaches to combat COVID-19. Here, we asked whether lessons learned from nanotoxicology and nanomedicine could shed light on the current pandemic. SARS-CoV-2, the causative agent, may trigger a mild, self-limiting disease with respiratory symptoms, but patients may also succumb to a life-threatening systemic disease. The host response to the virus is equally complex and studies are now beginning to unravel the immunological correlates of COVID-19. Nanotechnology can be applied for the delivery of antiviral drugs or other repurposed drugs. Moreover, recent work has shown that synthetic nanoparticles wrapped with host-derived cellular membranes may prevent virus infection. We posit that nanoparticles decorated with ACE2, the receptor for SARS-CoV-2, could be exploited as decoys to intercept the virus before it infects cells in the respiratory tract. However, close attention should be paid to biocompatibility before such nano-decoys are deployed in the clinic.

Keywords: bio-mimicking particles; coronavirus; cytokine storm; nanomedicine; nanosafety.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use
  • Betacoronavirus / drug effects
  • Betacoronavirus / physiology
  • COVID-19
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / metabolism
  • Coronavirus Infections / therapy*
  • Drug Delivery Systems / methods
  • Drug Repositioning / methods
  • Humans
  • Models, Molecular
  • Nanomedicine / methods*
  • Nanoparticles / therapeutic use
  • Nanotechnology / methods
  • Pandemics
  • Peptidyl-Dipeptidase A / metabolism
  • Peptidyl-Dipeptidase A / therapeutic use
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / metabolism
  • Pneumonia, Viral / therapy*
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2